ARDX vs. PRTC, BCYC, AMRX, PHAR, RNA, DYN, IRON, COLL, RAPT, and ARCT
Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include PureTech Health (PRTC), Bicycle Therapeutics (BCYC), Amneal Pharmaceuticals (AMRX), Pharming Group (PHAR), Avidity Biosciences (RNA), Dyne Therapeutics (DYN), Disc Medicine Opco (IRON), Collegium Pharmaceutical (COLL), RAPT Therapeutics (RAPT), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical preparations" industry.
Ardelyx vs.
PureTech Health (NASDAQ:PRTC) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.
PureTech Health has a net margin of 0.00% compared to Ardelyx's net margin of -104.52%. PureTech Health's return on equity of 0.00% beat Ardelyx's return on equity.
PureTech Health currently has a consensus price target of $55.00, suggesting a potential upside of 96.43%. Ardelyx has a consensus price target of $6.25, suggesting a potential upside of 57.04%. Given PureTech Health's higher possible upside, equities analysts clearly believe PureTech Health is more favorable than Ardelyx.
In the previous week, Ardelyx had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Ardelyx and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.87 beat Ardelyx's score of 1.45 indicating that PureTech Health is being referred to more favorably in the media.
0.3% of PureTech Health shares are owned by institutional investors. Comparatively, 40.4% of Ardelyx shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 5.5% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
PureTech Health has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.
PureTech Health has higher earnings, but lower revenue than Ardelyx.
Ardelyx received 493 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 67.39% of users gave Ardelyx an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.
Summary
Ardelyx beats PureTech Health on 8 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
